Navigation Links
ViroPharma to Release 2010 Second Quarter Financial Results on July 28, 2010

EXTON, Pa., July 21 /PRNewswire-FirstCall/ -- ViroPharma Incorporated's (Nasdaq: VPHM) second quarter financial results for 2010 are expected to be released on Wednesday, July 28, 2010 before the open of the U.S. financial markets.

The company will host a conference call and live audio webcast at 9:00 a.m. Eastern Time on the same day.  During the conference call, ViroPharma management will discuss the 2010 second quarter financial results and other business.

The press release and the live webcast of the conference call will be accessible via ViroPharma's corporate website at .  An audio archive will be available at the same address until August 16, 2010.  To participate in the conference call, please dial (888) 299-4099 (domestic) and (302) 709-8337 (international).  After placing the call, please tell the operator you wish to join the ViroPharma investor conference call.  

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products for physician specialists to enable the support of patients with serious diseases for which there is an unmet medical need, and providing rewarding careers to employees.  ViroPharma commercializes Cinryze™ (C1 esterase inhibitor [human]) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE).  ViroPharma commercializes Vancocin®, approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information on ViroPharma's commercial products, please download the package inserts at  ViroPharma currently focuses its drug development activities in diseases including C1 esterase inhibitor deficiency and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, The company encourages investors to consult these sections for more information on ViroPharma and our business.

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ViroPharma to Present at Three September Healthcare Conferences
2. ViroPharma to Present at Three October Healthcare Conferences
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
5. ViroPharma to Present at Three November Healthcare Conferences
6. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
7. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
8. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
9. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
10. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
11. ViroPharma to Present at Two June Healthcare Conferences
Post Your Comments:
(Date:11/27/2015)... November 27, 2015 ... popularity of companion diagnostics is one of ... market with pharmaceutical companies and diagnostic manufacturers ... tests. . --> ... report on global cancer biomarkers market spread ...
(Date:11/25/2015)... , Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: ... adopted a stockholder rights plan (Rights Plan) in an ... loss carryforwards (NOLs) under Section 382 of the Internal ... --> PharmAthene,s use of its NOLs could be ... as defined in Section 382 of the Code. In ...
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. ... Gorman , President and CEO of Neurocrine Biosciences, will ... Conference in New York . ... visit the website approximately 5 minutes prior to the ... replay of the presentation will be available on the ...
(Date:11/25/2015)... 2015 The Global Genomics ... professional and in-depth study on the current state ... ) , The report ... definitions, classifications, applications and industry chain structure. The ... markets including development trends, competitive landscape analysis, and ...
Breaking Biology Technology:
(Date:11/9/2015)... , Nov. 09, 2015 ... the addition of the "Global Law ... their offering. --> ) ... "Global Law Enforcement Biometrics Market 2015-2019" ... Research and Markets ( ) has ...
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has been ... provide preclinical development services to the National Cancer Institute ... will provide scientific expertise, modern testing and support facilities, ... preclinical pharmacology and toxicology studies to evaluate potential cancer ... The PREVENT Cancer Drug Development Program is an ...
(Date:10/29/2015)... Oct. 29, 2015 Daon, a global leader ... has released a new version of its IdentityX ... North America have already installed IdentityX ... includes a FIDO UAF certified server component ... to activate FIDO features. These customers include some of ...
Breaking Biology News(10 mins):